TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12096825
Drug: EE/DRSP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (30 microg ethinyl estradiol / 3 mg drospirenone)
Study: 12096825
Drug: EE/CPA (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CPA (35 microg ethinyl estradiol / 2 mg cyproterone acetate)
Study: 10616770
Drug: 30mg LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid for 2 weeks
Study: 10616770
Drug: 30mg LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid for 1 week
Study: 8847197
Drug: Usual hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual hospital ward treatment with neuroleptic drugs
Study: 1971166
Drug: Cocaine administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administration (2 mg/kg body weight)
Study: 1971166
Drug: Intracoronary propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary propranolol administration (2 mg in 5 minutes)
Study: 1971166
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration (control)
Study: 25350366
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg/day for 7 days, then 10 mg/day for 7 days)
Study: 24332919
Drug: Mannitol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (0.5 g/kg) plus hydration
Study: 17846129
Drug: Dihydroartemisinin-piperaquine (DHP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHP) treatment
Study: 25597438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxycodone and pregabalin (B1 group)
Study: 25597438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxycodone and pregabalin (B2 group)
Study: 25597438
Drug: Oxycodone (A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (A1 group)
Study: 25597438
Drug: Oxycodone (A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (A2 group)
Study: 19936416
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (Group D, n=42)
Study: 19936416
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride infusion (Group P, n=39)
Study: 3429697
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine, sublingually administered
Study: 3429697
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral nifedipine, 10 mg qid
Study: 29679670
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for 8 weeks
Study: 22545424
Drug: Oral lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lornoxicam (8 mg)
Study: 22545424
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (500 mg)
Study: 22545424
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (lornoxicam and paracetamol)
Study: 18450380
Drug: Epoprostenol (PGI(2))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol (PGI(2)) infusion at 10 ng/kg/min for 25 min
Study: 18450380
Drug: Epoprostenol (PGI(2))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol (PGI(2)) infusion
Study: 16835477
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen (CPT‐11 180 mg/m(2) as a 90‐min infusion on day 1, l‐LV 200 mg/m(2) as a 2‐h infusion during CPT‐11, followed by a bolus dose of 5‐FU 400 mg/m(2) and a 46‐h continuous infusion of 2,400 mg/m(2) every 2 weeks)
Study: 16835477
Drug: oxaliplatin/5‐FU/LV therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin/5‐FU/LV therapy (FOLFOX)
Study: 11737921
Drug: Activated protein
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated protein C and low-dose steroids in sepsis
Study: 8442393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyridamole 75 mg and acetylsalicylic acid 330 mg t.i.d.
Study: 31347611
Drug: Gepirone extended-release
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone extended-release tablets (gepirone ER, Travivo)
Study: 27795670
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous dexamethasone (DM group)
Study: 24413969
Drug: PCIT maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIT maintenance treatment (MT)
Study: 9829223
Drug: Thyroid replacement
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid replacement therapy (L-thyroxine) for 3 months
Study: 8160095
Drug: Percutaneous radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous radiation therapy (12.5 Gy total dose over 5 days with 2.5 Gy per day)
Study: 8160095
Drug: Stent implantation
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent implantation alone (no radiation therapy)
Study: 1096537
Drug: Lithium citrate
Normalized name: Lithium Citrate
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium citrate in slow release tablets
Study: 30783682
Drug: Vatelizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatelizumab (monoclonal antibody targeting α2 subunit of VLA-2)
Study: 26006137
Drug: Postoperative statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative statin therapy (atorvastatin 40 mg per day starting 6 hours after operation)
Study: 26006137
Drug: Non-statin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin group (no postoperative statin therapy)
Study: 26006137
Drug: Postoperative atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative atorvastatin
Study: 21627686
Drug: Higher-dose angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose angiotensin receptor blockers
Study: 21627686
Drug: Lower-dose angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose angiotensin receptor blockers
Study: 19320697
Drug: Personalised Advice‐giving;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised Advice‐giving; combination of 'Information Management' activities and 'Interactive Orientation'
Study: 16764345
Drug: Oral levocarnitine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levocarnitine, 3-6 g daily
Study: 16764345
Drug: Immunosuppressive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive or immunomodulatory therapies
Study: 9470829
Drug: rIFN-gamma 4
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma 4 million units (0.2 mg) subcutaneously every other day for 4 months
Study: 9470829
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no maintenance therapy)
Study: 7895954
Drug: Hypoglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) with 90 degrees headup posture
Study: 7895954
Drug: Hypoglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) with return to supine posture
Study: 7895954
Drug: Hypoglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (blood glucose 2.5 mmol/l) after 40 min
Study: 7895954
Drug: Euglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (blood glucose 5.0 mmol/l) using a hyperinsulinaemic clamp
Study: 2879101
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram dose of Merck, Sharp and Dohme plasma vaccine
Study: 2879101
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms dose of Merck, Sharp and Dohme plasma vaccine
Study: 2879101
Drug: Three 2
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 2 micrograms doses of vaccine
Study: 31318424
Drug: Serologic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serologic testing for anti-measles virus IgG antibody in a subsample of survey participants.
Study: 22383680
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) plus adjuvant systemic therapy
Study: 22383680
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy alone (Control)
Study: 19269753
Drug: VAC BNO
Normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC BNO 1095 extract (40mg herbal drug)
Study: 16763787
Drug: Anvirzel (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anvirzel (0.1, 0.2, 0.4, 0.8, 1.2 ml/m2/day)
Study: 12783047
Drug: C+E (Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (Caffeine 4 mg x kg‐1 + Ephedrine 0.8 mg x kg‐1)
Study: 12783047
Drug: E (Ephedrine
Normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (Ephedrine 0.8 mg x kg‐1)
Study: 12783047
Drug: C (Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (Caffeine 4 mg x kg‐1)
Study: 3758239
Drug: Nebuhaler (terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler (terbutaline 0.10 mg/kg)
Study: 3758239
Drug: Nebulizer (terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer (terbutaline 0.10 mg/kg)
Study: 24089509
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group with a 50% higher stimulated C-peptide on entry (from 0.10 to 0.15 nmol/L)
Study: 24089509
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group with a 50% higher stimulated C-peptide on entry
Study: 22789125
Drug: Eltrombopag (12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (12.5mg to 50mg daily)
Study: 16518002
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing (ODD) - 160 mg once daily
Study: 16518002
Drug: Pharmacokinetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic dosing (TCI) - 160 mg once daily initially, dose revised based on serum drug levels
Study: 16518002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - 80 mg gentamicin twice daily
Study: 12439841
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily on the day before and the day of contrast administration with hydration
Study: 9719082
Drug: DFMO 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.20 g/m2
Study: 9719082
Drug: DFMO 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.40 g/m2
Study: 9719082
Drug: DFMO (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (all doses)
Study: 9719082
Drug: DFMO (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (0.20 g/m2 and 0.40 g/m2)
Study: 4919027
Drug: Oral L-DOPA
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral L-DOPA
Study: 4919027
Drug: Standard agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard agents
Study: 25989732
Drug: FAHT cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAHT cream
Study: 23884317
Drug: Distress Tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distress Tolerance (DT) treatment (9 2-hr group and 6 50-min individual sessions) plus 8 weeks of transdermal nicotine patch
Study: 23884317
Drug: Standard Smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Smoking Treatment (ST) (6 90-min group and 1 20-min individual session) plus 8 weeks of transdermal nicotine patch
Study: 29927279
Drug: Distress Tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distress Tolerance (DT) treatment
Study: 21854342
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg once daily in the morning (QD AM)
Study: 21854342
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg twice daily (BID)
Study: 21854342
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 200 μg once daily in the morning (QD AM)
Study: 16567155
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (3.6 g/kg/day)
Study: 16567155
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein (1.8 g/kg/day)
Study: 16567155
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein (0.8 g/kg/day)
Study: 12507714
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine given 4-hourly
Study: 12507714
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine given once daily
Study: 10844490
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg i.m.
Study: 10844490
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg i.m.
Study: 1625204
Drug: Cocaine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Study: 8229755
Drug: Mazindol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (0, 1 and 2 mg given orally 2 hr before the cocaine injection)
Study: 30246320
Drug: Inhaled procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled procaterol
Study: 18719756
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (control)
Study: 10493325
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist evaluation including medication evaluation, therapeutic recommendations, patient education, and follow-up telemonitoring
Study: 1722704
Drug: Scatter photocoagulation
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scatter photocoagulation treatment
Study: 24465617
Drug: High-dose micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose micronutrient and anti-oxidant supplementation
Study: 24465617
Drug: Recommended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended daily allowance (RDA) vitamins
Study: 18408402
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for breast cancer
Study: 18408402
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for cervix cancers
Study: 18408402
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for cervix pre-cancers
Study: 11786110
Drug: LdCa (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LdCa (1.25 mmol/L)
Study: 11786110
Drug: dCaP (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCaP (1.25 mmol/L for first 2 hours, 1.75 mmol/L for last 2 hours)
Study: 11786110
Drug: MdCa (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MdCa (1.5 mmol/L)
Study: 7861833
Drug: Prophylactic amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic amphotericin B (AmB) at a dose of 0.5 mg/kg/48 h from day + 1 BMT until hemoperipheral recovery (group A)
Study: 2683457
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine (0.55 microgram active components, administered intermittently over six months)
Study: 2683457
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine (6 or 9 capsules per day)
Study: 31533750
Drug: Modified SB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified SB (600 mg·kg‐1 over 19.5 h)
Study: 31533750
Drug: Acute SB
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute SB (300 mg·kg‐1)
Study: 16116682
Drug: Nebulized fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized fluticasone propionate (FP) 250 mcg twice daily for 10 days
Study: 16116682
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (BUD) 500 mcg twice daily for 10 days
Study: 10466475
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg twice daily (n = 9)
Study: 10466475
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg twice daily (n = 8)
Study: 2192585
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg administered orally
Study: 526401
Drug: Diazoxide 300
Normalized name: diazoxide 300 mg/20 mL INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide 300 mg
Study: 526401
Drug: Labetalol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 150 mg
Study: 31000180
Drug: S (‐)
Normalized name: Esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S (‐) amlodipine (2.5 mg)
Study: 26938750
Drug: Sildenafil OSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil OSF 100 mg formulations
Study: 26938750
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 100 mg tablets
Study: 6752963
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam suppositories
Study: 19213575
Drug: Interscalene continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene continuous infusion of 2% ropivacaine (2 mL/h)
Study: 19213575
Drug: Subacromial continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial continuous infusion of 2% ropivacaine (2 mL/h)
Study: 15123230
Drug: Budesonide/formoterol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (1 inhalation)
Study: 7720476
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg, single intravenous dose)
Study: 2297461
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral loperamide (4 doses)
Study: 2297461
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg oral loperamide (1 dose)
Study: 2297461
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg oral loperamide (2 doses)
Study: 30711321
Drug: Daily dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dressing
Study: 30711321
Drug: Weekly dressing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dressing
Study: 24700581
Drug: Immediate-release opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release opioid (oxycodone or morphine)
Study: 21705873
Drug: CUIDATE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUIDATE group (multidimensional physical therapy program)
Study: 10233317
Drug: MPD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPD regimen starting with 50% of the minimal phototoxic dose (MPD) with weekly increments of 40%, 30%, 25%, 20%, 15%, 10% and 5% to a maximum of 14.5 J/cm2
Study: 10233317
Drug: Skin type
Normalized name: CVS Skin Tag Remover For All Skin Types Homeopathic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin type regimen starting with a fixed dose based on skin type with weekly dose increments of 40%, decreasing to 20% once erythema develops
Study: 10233317
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (MPD and skin type regimen)
Study: 28182820
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Resveratrol (RSVhigh)
Study: 28182820
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Resveratrol
Study: 22000728
Drug: Dialysate tCa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate tCa concentration of 3.0 mEq/L
Study: 22000728
Drug: Dialysate tCa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate tCa concentration of 2.75 mEq/L
Study: 22000728
Drug: Dialysate tCa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate tCa concentration of 2.5 mEq/L
Study: 19199349
Drug: Axillary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary treatment (dissection or radiotherapy)
Study: 31098832
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of 6% CHO mouth rinse
Study: 24833043
Drug: bilastine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilastine (20 mg)
Study: 24833043
Drug: hydroxyzine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyzine (25 mg)